Acrivon Historical Balance Sheet
| ACRV Stock | 7.52 0.17 2.31% |
Trend analysis of Acrivon Therapeutics, Common balance sheet accounts such as Short Long Term Debt Total of 4.2 M, Other Current Liabilities of 3.4 M or Total Current Liabilities of 14 M provides information on Acrivon Therapeutics,'s total assets, liabilities, and equity, which is the actual value of Acrivon Therapeutics, to its prevalent stockholders. By breaking down trends over time using Acrivon Therapeutics, balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Acrivon Therapeutics, latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Acrivon Therapeutics, is a good buy for the upcoming year.
Acrivon |
About Acrivon Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Acrivon Therapeutics, at a specified time, usually calculated after every quarter, six months, or one year. Acrivon Therapeutics, Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Acrivon Therapeutics, and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Acrivon currently owns. An asset can also be divided into two categories, current and non-current.
Acrivon Therapeutics, Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Acrivon Therapeutics, assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Acrivon Therapeutics, books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Acrivon Therapeutics, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Acrivon Therapeutics, Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most accounts from Acrivon Therapeutics,'s balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Acrivon Therapeutics, current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acrivon Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Acrivon Therapeutics,'s Total Current Liabilities is fairly stable compared to the past year. Net Tangible Assets is likely to climb to about 205.8 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 4.2 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 5.6M | 5.0M | 4.6M | 4.2M | Total Assets | 106.6M | 181.2M | 138.3M | 117.8M |
Acrivon Therapeutics, balance sheet Correlations
Click cells to compare fundamentals
Acrivon Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.